In addition to consulting guidances, sponsors are encouraged to contact the division to discuss specific issues that arise during drug development. FSIAD is a clinical entity described in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) that was published in 2013, w